Adherence to oral hormonal anticancer agents in breast cancer.
Adherence
adjuvant endocrine therapy
breast cancer
oral antitumoral agents
Journal
Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
6
6
2023
pubmed:
24
5
2022
entrez:
23
5
2022
Statut:
ppublish
Résumé
There is an increasing trend towards using oral antitumoral agents in oncological patients. Compared to parenteral therapy, oral treatment offers convenience for both the patient and the healthcare system, with similar efficacy. However, the benefit deriving from oral drugs will be obtained only if patients adhere strictly to the treatment. Medical oncologists must therefore seek to optimize patient adherence. Breast cancer patients, particularly, are often treated with oral hormonal anticancer agents. In this review, we summarized evidence about adherence of breast cancer patients to oral hormonal anticancer agents and the consequences of poor compliance, the barriers to oral treatment and strategies to overcome them.
Identifiants
pubmed: 35603579
doi: 10.1177/03008916221096183
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM